4
Clinical Trials associated with OPC-131461A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Doseranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])
Start Date10 Jan 2023 |
Sponsor / Collaborator- |
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Doseranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])
To investigate the dose response in respect of weight decrease following repeated oral administration of OPC-131461 at 1, 2, 5, and 10 mg or placebo in patients with CHF with volume overload despite having received diuretics other than vasopressin antagonists
A Single-center, Randomized, Open-label, 2-Cohort, 2-Period Crossover Trial to Investigate the Relative Bioavailability of OPC-131461 Oral Suspension and OPC-131461 Tablet and the Food Effect on the Pharmacokinetics of OPC-131461 in Healthy Adult Male Subjects (Phase 1 Trial)
Start Date22 Jan 2022 |
Sponsor / Collaborator- |
100 Clinical Results associated with OPC-131461
100 Translational Medicine associated with OPC-131461
100 Patents (Medical) associated with OPC-131461
100 Deals associated with OPC-131461